Amundi
SUPN icon

Amundi’s Supernus Pharmaceuticals SUPN Stock Holding History

Amundi’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419K Sell
9,015
-1,748
-16% -$84K ﹤0.01% 1713
2026
Q1 		$556K Sell
10,763
-10,196
-49% -$519K ﹤0.01% 1510
2025
Q4 		$1.04M Buy
20,959
+10,855
+107% +$528K ﹤0.01% 1265
2025
Q3 		$488K Buy
10,104
+955
+10% +$38.5K ﹤0.01% 1337
2025
Q2 		$293K Buy
+9,149
New +$293K ﹤0.01% 1522

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Amundi's SUPN Position: Q2 2026 in Review

Amundi reduced its Supernus Pharmaceuticals (SUPN) stake by 16% in Q2 2026, selling an estimated $84K and leaving 9,015 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #1713.

Amundi first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.04M in Q4 2025. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Amundi held 9,015 shares of Supernus Pharmaceuticals worth $419K as of Q2 2026.
  • Amundi sold 1,748 Supernus Pharmaceuticals shares in Q2 2026, an estimated $84K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1713 holding.
  • Amundi first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Amundi's Supernus Pharmaceuticals position peaked at $1.04M in Q4 2025.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.